Lyell Immunopharma (NASDAQ:LYEL – Get Free Report) and Anika Therapeutics (NASDAQ:ANIK – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, earnings, risk, profitability and valuation.
Risk and Volatility
Lyell Immunopharma has a beta of -0.04, meaning that its stock price is 104% less volatile than the S&P 500. Comparatively, Anika Therapeutics has a beta of 0.2, meaning that its stock price is 80% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Lyell Immunopharma and Anika Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lyell Immunopharma | 1 | 1 | 6 | 1 | 2.78 |
| Anika Therapeutics | 1 | 0 | 2 | 1 | 2.75 |
Valuation and Earnings
This table compares Lyell Immunopharma and Anika Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lyell Immunopharma | $40,000.00 | 6,829.38 | -$274.45 million | ($12.83) | -0.87 |
| Anika Therapeutics | $112.82 million | 2.48 | -$10.88 million | ($0.27) | -77.37 |
Anika Therapeutics has higher revenue and earnings than Lyell Immunopharma. Anika Therapeutics is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Lyell Immunopharma and Anika Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lyell Immunopharma | -920,285.25% | -91.62% | -70.50% |
| Anika Therapeutics | -3.14% | 0.20% | 0.15% |
Institutional and Insider Ownership
66.0% of Lyell Immunopharma shares are owned by institutional investors. Comparatively, 91.5% of Anika Therapeutics shares are owned by institutional investors. 6.2% of Lyell Immunopharma shares are owned by company insiders. Comparatively, 12.1% of Anika Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Anika Therapeutics beats Lyell Immunopharma on 9 of the 14 factors compared between the two stocks.
About Lyell Immunopharma
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
About Anika Therapeutics
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company’s joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
Receive News & Ratings for Lyell Immunopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyell Immunopharma and related companies with MarketBeat.com's FREE daily email newsletter.
